The video explains the three main phases of a clinical trial. There are currently both preventive and therapeutic vaccines under development. In addition to work being done in the preclinical stage, there are several vaccines in clinical trials. More information on those listed below and other clinical trials can be found at ClinicalTrials. For more on the current status of herpes vaccine development, including vaccine candidates in the preclinical phase, see this article prepared for the WHO Product Development Vaccine Advisory Committee.
Email us at communications fredhutch. Donate Now. Hutch News Stories. A cure for herpes? There is progress to report. Mouse studies show gene therapy can cause big drop in latent infections. Martine Aubert, a senior staff scientist in the Fred Hutch laboratory of Dr. Keith Jerome, carried out the meticulous research that steadily improved the results of efforts to eradicate herpes simplex virus in mice.
It takes a persistent scientist to stop a persistent virus. Nevertheless, she persisted. What breakthroughs are coming next? Sign up for news. Support Fred Hutch Research Give now. Improvements in gene-editing tools — and patience — keys to success The advances in herpes cure research over the past five years are largely due to a series of improvements in the gene editing tools. A workhorse of gene therapy The researchers also refined their methods of transporting the molecular scissors to targeted nerve cells.
Fred Hutch structural biologist Dr. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials.
Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details.
Results First Posted : July 13, Last Update Posted : July 13, Study Description. The purpose of this study is to evaluate the effect of recombinant human heat shock protein polyvalent peptide complex HerpV vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment. Detailed Description:. Knipe and Jeffrey Cohen, M. The experimental product is a replication-defective vaccine, meaning that scientists have removed two key proteins from the vaccine virus so that it cannot multiply to cause genital herpes.
The clinical trial is expected to enroll 60 adults ages 18 to 40, who will be divided into three groups of 20 participants each. The investigational vaccine is being tested among study participants who have previously been infected with HSV to determine if it may pose any safety issues.
Within each of the three groups, researchers will randomly assign participants to receive three doses 0. The three vaccinations will occur at study enrollment and again one month and six months later. Participant safety will be monitored throughout the course of the trial, and researchers will follow participants for six months after they have received their last dose of vaccine.
0コメント